Blood Testing Market: Market Size & Forecast 2026

The blood testing market involves the collection, analysis, and interpretation of blood samples to detect diseases, monitor patient health, and inform medical treatment decisions. It encompasses a broad range of tests including complete blood counts, metabolic panels, infectious disease screening, and specialized diagnostic assays used in hospitals, independent diagnostic centers, and point-of-care settings. The market is supported by laboratory infrastructure worldwide and relies on commercial research estimates for revenue data, as government bodies track safety standards but do not compile comprehensive global market statistics.

• •Market valued at approximately $105 billion in 2025
• •Growth projections range from 7.0% to 8.83% CAGR depending on forecast horizon
• •Revenue data sourced from commercial research as official global market estimates are not published by government agencies

Rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer creates sustained and growing demand for blood-based diagnostic testing. Preventative healthcare awareness and government health initiatives are encouraging routine screening and early disease detection among broader populations. Technological advancements in automated laboratory analyzers are improving efficiency, accuracy, and throughput in clinical laboratories, while expanded government healthcare spending enables greater access to diagnostic services in both developed and emerging markets.

• •Rising chronic disease prevalence worldwide driving consistent demand for diagnostic services
• •Preventative healthcare awareness and government initiatives promoting routine screening
• •Government healthcare spending expansion and automation technologies improving laboratory efficiency

The market spans traditional clinical chemistry tests, blood screening for transfusions, and specialized segments like oncology blood testing that employs liquid biopsy assays for non-invasive cancer detection. The oncology blood testing segment alone is projected to grow from $5.9 billion in 2025 to $24.2 billion by 2035 at a 15.2% CAGR, reflecting rapid adoption of early cancer diagnostic tools. While specific regional breakdowns vary across studies, market expansion is occurring globally as healthcare infrastructure develops in emerging economies alongside mature markets.

• •Oncology blood testing segment forecasted at 15.2% CAGR, reaching $24.2 billion by 2035
• •Blood screening market valued at $4.2 billion in 2025, expanding at 12.2% CAGR
• •Growth distributed across developed and emerging healthcare markets worldwide

What are the recent trends and outlook?

Automation and integration of laboratory systems continue to transform operational efficiency, data management, and workflow optimization in blood testing environments. Liquid biopsy technology and minimally invasive cancer diagnostics represent particularly dynamic trends, enabling earlier cancer detection and monitoring through blood samples rather than tissue biopsies. Point-of-care testing is expanding access to rapid results outside traditional laboratory settings, supporting decentralized healthcare models and faster clinical decision-making. The market is expected to maintain robust growth through 2035 as aging populations, emerging market healthcare development, and ongoing medical innovation collectively sustain and accelerate demand.

• •Liquid biopsy and early cancer diagnostics emerging as high-growth applications
• •Automation and point-of-care testing expanding access, efficiency, and decentralized healthcare delivery
• •Market projected to reach $160-224 billion range by 2030-2035 across various forecast models